Animal Study Links SNAC, the Absorption Enhancer in Ozempic and Wegovy Pills, to Gut and Inflammation Changes

Over 21 days, researchers repeatedly exposed animals to SNAC, the ingredient that lets semaglutide survive the stomach and reach the bloodstream in pill form, and then looked at what changed. The answer, published as the first in vivo study to systematically examine repeated SNAC exposure, was a list of shifts in the gut, the blood, and the brain.

The team recorded a decline in beneficial gut bacteria that break down dietary fibre. Levels of short chain fatty acids, which support the gut lining and help control inflammation, were lower. Inflammatory markers in the blood rose. The animals had greater liver weight, which can be a sign of low grade inflammation, and a smaller cecum, the part of the intestine where bacteria ferment fibre and produce protective compounds. Levels of a brain derived protein associated with cognitive impairment were also reduced.

The context is the arrival of semaglutide as a tablet. Semaglutide is the active drug in Wegovy and Ozempic. Injected, it goes straight into the bloodstream. Swallowed, it needs SNAC to shield it from stomach enzymes and help it cross into the blood. Without SNAC, oral semaglutide would not work. The United States approved a tablet version of Wegovy late last year, and because pills are often seen as more convenient and potentially cheaper than injections, daily exposure to SNAC could climb substantially as more people switch.

Demand is already large. Around 890 million adults and 160 children worldwide live with obesity, roughly one in eight people. Among OECD countries, the United States has the highest rate, with 43% of people aged 15 and over affected. Australia ranks sixth at 31%, above the OECD average of 25%. Prescriptions for Ozempic and Wegovy have risen rapidly in Australia in recent years, mirroring global trends.

Lead author Amin Ariaee, a PhD candidate at Adelaide University, framed the work as a matter of completeness. "Obesity is a complex, chronic disease with serious health consequences. These medicines are highly effective and are helping many people," he said. But as oral versions spread, he argued, researchers need to understand what repeated, long term exposure to every ingredient in the pill means, not only the active drug. He said SNAC was associated with shifts in potentially harmful gut bacteria, elevated inflammatory markers and depletion of proteins linked to cognitive impairment, and that the findings warrant further investigation.

Senior Research Fellow Dr. Paul Joyce was careful about the limits. The results come from animal research and should be read with caution. "Importantly, our findings do not prove that SNAC causes harm in humans," he said. He added that they do suggest the ingredient enabling the tablets to work may have adverse biological effects beyond drug absorption. Because these medicines are typically taken daily and often for long periods, he said, all components of the therapies deserve evaluation.

So the study establishes associations in animals over three weeks, not harm in patients. What to watch is whether further work tests SNAC exposure over longer periods and in people, as oral obesity treatments become more widely used.